Dermatology
From the Journals
Isotretinoin not associated with increased depression risk, in meta-analysis
A meta-analysis of 31 studies addresses the controversial issue: Does isotretinoin therapy increase the risk of depression in patients with acne...
Conference Coverage
Stem cell therapy significantly improves ulcer healing
PORTLAND, ORE. – Treating chronic venous leg ulcers with mesenchymal stem cells and fibrin spray significantly improved wound healing.
Conference Coverage
Mole count predicted melanoma death, especially among men
PORTLAND, ORE. – Could the number of cutaneous nevi among white men and women be used to help predict their risk of death from melanoma?
Conference Coverage
Modern estrogen ‘microdoses’ in contraceptives did not increase risk of melanoma
PORTLAND, ORE. – The null results of a retrospective cohort study belied decades-old studies that linked contraceptives containing much higher...
Conference Coverage
Benefits, safety of dupilumab-steroid combination in adults with AD sustained
The one-year results of a multinational study comparing dupilumab plus topical steroids provide encouraging longterm safety and efficacy data for...
Conference Coverage
Infliximab biosimilar noninferior to originator in IBD – NOR-SWITCH
CHICAGO – Can use of biosimilars save money for IBD patients and health care systems?
Conference Coverage
Treatment challenges for lichen planopilaris
SYDNEY – Just over half of patients with lichen planopilaris in a medical record review responded to first-line therapies, but response rates...
Conference Coverage
Skin cancer risk similar for liver and kidney transplant recipients
A survey of nonmelanoma skin cancers among liver and kidney transplant recipients provided important information about the implications for skin...
Conference Coverage
Study links photosensitizing antihypertensives to SCC
PORTLAND, ORE. - The results have implications for skin cancer screening and prevention for patients on these drugs.
From the Journals
Adalimumab outperforms methotrexate in treating severe pediatric plaque psoriasis
A phase III study provided promising data on the efficacy of adalimumab in children and adolescents with severe plaque psoriasis.
Conference Coverage
CC-220 shows efficacy, safety concerns in phase II SLE trial
The investigational agent CC-220 showed some efficacy but also important safety caveats in a 12-week, phase II trial.